tbuckley/cabot-search huggingface dataset:
Health care utilization (HCU) by breast cancer (BC) and non-Hodgkin lymphoma (NHL) patients (pts) with chemotherapy (CT) induced febrile neutropenia (FN) in the Netherlands.
Authors: Hans Gelderblom, Pieternella Lugtenburg, J. W. R. Nortier, Myrthe van Herk-Sukel, Djamila Issa, A. Jager, Margarita De La Orden, Mirte van der Werf-Langenberg, Leanne Houweling, Floris Aart De Jong
Journal: Journal of Clinical Oncology (2012)

e16526 Background: CT-induced FN can result in reduced CT delivery, unplanned hospitalizations, and increased mortality risk. Changes in clinical practice warrant investigation of current resource use and economic cost of FN; therefore we studied FN-related HCU among BC and NHL pts. Methods: Data from incident adult cancer pts with a primary hospital discharge diagnosis for BC or NHL from 1998–2007 were obtained from the PHARMO Record Linkage System, including pharmacy, hospital and clinical lab data. Eligible pts had ≥12 months medical history available and received CT ≤6 months after cancer diagnosis. Pts developing FN ≤6 months after first CT (“FN pts”) were matched 1:2 on gender, birth year, and CT regimen to pts without FN (“non FN pts”). HCU data (hospitalizations, medical procedures, drug use [number dispensed]) was tallied from entry date (date of FN or matched date for non FN pts) for up to 3 months. Statistics are descriptive with crude odds ratios (OR). Results: 80/1,033 BC pts (8%) developed FN (all were matched). 95/486 NHL pts (20%) developed FN (89 were matched). More FN than non FN pts were hospitalized in the 1st month after the entry date: BC 73% vs 14% (OR=23.0 [95%CI 8.3-63.7]); NHL 78% vs 33% (OR=7.6 [3.9-15.1]). These differences were mainly due to FN-related hospitalizations (BC 55% vs 1%, NHL 47% vs 4%). FN pts also had a longer mean length of stay per all-cause hospitalization: BC 4.6 vs 1.9 days; NHL 10.1 vs 3.0 days. In the 1 st month after entry date, the mean number of total drugs dispensed per patient was higher in FN pts than non FN pts (BC 5.8 vs 3.1, NHL 8.5 vs 3.6); use of anti-infectious agents was higher (BC 99% vs 11%, NHL 96% vs 20%), as was number of other non-CT drugs (including corticosteroids, drugs for acid related disorders, laxatives, psycholeptics, analgesics, antithrombotics, and diuretics). More FN than non FN pts had medical procedures (BC 14% vs 3%, NHL 13% vs 8%). HCU differences between FN and non FN pts were maintained after 3 months. Conclusions: This study confirms the high resource utilization currently associated with FN, based on BC and NHL pt data from the Netherlands. Reduction of FN may improve quality of life and save resources.
Herpes simplex lesion mimicking left upper lobe bronchial tumour
Authors: George Caldas Dantas, Hamilton Shoji, Cristiane Hoelz, Marcelo Buarque de Gusmão Funari, Gilberto Szarf
Journal: Thorax (2017)

A 76-year-old male patient presented with fever, cough and dyspnoea for 4 days. His history included chemotherapy for chronic lymphoid leukaemia concluded 2 years before and use of ibrutinib and hyperimmune globulin for the last year. On chest X-ray, it was possible to identify complete atelectasis of the left upper lobe (LUL) (figure 1A, B). CT demonstrated a mass-like lesion causing obstruction of the respective lobar bronchus (figure 1C, D). The lesion showed intense focal abnormal uptake on fluorodeoxyglucose positron emission tomography/CT (figure 2A). There were no enlarged or hypermetabolic lymph nodes. Bronchoscopy demonstrated polypoid lesions occluding the LUL bronchus (figure 2B). Bronchoalveolar lavage was negative for neoplastic cells and obtained metaplastic and mature squamous epithelial cells with cytopathic changes, compatible with viral …
Whole Exome Analysis of Relapsing Patients with Acute Promyelocytic Leukemia
Authors: Cecile Bally, Jacqueline Lehmann-Che, Bruno Cassinat, Lionel Ades, Eric Letouze, Pierre Hirsch, Marie-Joelle Mozziconacci, Sophie Raynaud, Eric Delabesse, Madalina Uzunov, Mathilde Hunault, Eric Lippert, Hélène Lapillonne, Christophe Ferrand, Carine Gervais, Nathalie Gachard, Agnès Guerci, Pierre Fenaux, Hugues de The
Journal: Blood (2016)
Seroprevalence of five neglected parasitic diseases among immigrants accessing five infectious and tropical diseases units in Italy: a cross-sectional study
Authors: G. Martelli, C. Di Girolamo, L. Zammarchi, A. Angheben, M. Morandi, S. Tais, M. Degani, I. El Hamad, S. Caligaris, A. Ciannameo, E. Grilli, L. Urbinati, G.B. Monteiro, C. Scarcella, N. Petrosillo, M. Digaetano, L. Rabbi, N. Bazzanini, F. Cacciatore, B.L. Marta, M.L. Moro, A. Bartoloni, P. Viale, G. Verucchi
Journal: Clinical Microbiology and Infection (2017)
Significance of Busulfan Dose Intensity On Outcomes of Hematopoietic Cell Allografting for AML in Second Complete Remission or Beyond: A Report From the EBMT Acute Leukemia Working Party
Authors: Ali Bazarbachi, Myriam Labopin, Mohamed A. Kharfan-Dabaja, Gérard Socié, Nicolaus Kröger, Didier Blaise, Hendrik Veelken, Arancha Bermudez, Reuven Or, Bruno Lioure, Dietrich Beelen, Nathalie Fegueux, Rose-Marie Hamljadi, Arnon Nagler, Mohamad Mohty
Journal: Blood (2012)
In Reply:
Authors: Daniele Laszlo, Alberto Agazzi, Giancarlo Pruneri, Francesco Bertoni, Liliana Calabrese, Giovanni Martinelli
Journal: Journal of Clinical Oncology (2005)

performed during follow-up.Therefore, these positive results should be assessed as persistent minimal residual disease because t(11;18)(q21;q21) does not occur in normal B cells.Of note, rearrangements of the IgH gene were not detected in our third patient, a fact that suggests that RT-PCR for t(11;18)(q21;q21) is more sensitive for detecting minimal residual disease in this context.In patients with indolent lymphomas, the use of rituximab as a single agent has shown a response rate of approximately 50% to 75% and 40% to 60% in previously untreated and in relapsed patients, respectively.These figures are similar to those obtained by Martinelli et al 1 in their series of gastric MALT lymphoma treated with the same schedule of rituximab.In addition, maintenance therapy with rituximab is increasingly being used to eliminate minimal residual disease, further delaying or preventing disease relapse.In follicular lymphoma, several studies have recently demonstrated a prolonged event-free and progression-free survival in those patients who were treated with rituximab maintenance. 9Because of this, we treated our first two patients with two cycles of rituximab, spaced 6 months between them, in order to improve the response.Treatment was well tolerated but, no significant histologic changes could be seen and residual disease was persistently found 2 months after rituximab and in all samples taken during follow-up.Our experience is in accordance with the evidence that gastric MALT lymphoma associated with t(11;18)(q21;q21) does respond to chemotherapy.However, residual disease can be found in these patients, both microscopically and by PCR, although the clinical significance of this finding remains uncertain.In our experience, the best method of follow up for these patients is RT-PCR for t(11;18)(q21;q21) instead of PCR for the IgH gene.Because t(11;18)(q21;q21)-positive cells are capable of surviving and remaining dormant for a long period, we suggest that long-term molecular follow-up is reasonable in these patients.
Diverse Roles of Hepatocyte Growth Factor (HGF) in Normal Karyotype Acute Myeloid Leukemia (AML).
Authors: Ian McInnis, Theresa Hahn, Anasitasia Ioane, Ashleigh Lamson, Deepika Lal, Laurie Ann Ford, Sheila NJ Sait, Petr Starostik, George Deeb, Meir Wetzler, Terry Mashtare, Eunice S. Wang
Journal: Blood (2009)
Standardized Ultrasonography (HEAD-US) of Joints and First Correlation with Function in Haemophilic Arthropathy: Results of a Clinical Trial and Potential Importance of Joint-Ultrasound for an Individualized Prophylaxis in Haemophiliacs
Authors: Michael Sigl-Kraetzig, Stefan Bauerfeindt, Amanda Wildner, Axel Seuser
Journal: Blood (2015)
Significance of Blast CD33 Expression for Effect of Gemtuzumab Ozogamicin at Different Doses in Adult Acute Myeloid Leukemia: Results from the UK NCRI AML16/17 Trials
Authors: Khan Naeem, Robert K. Hills, Paul Virgo, Stephen Couzens, Nithiya Clark, Amanda Gilkes, Angela Grech, Peter Richardson, Steven Knapper, David Grimwade, Nigel H. Russell, Alan K. Burnett, Sylvie Freeman
Journal: Blood (2015)
Visualization of Macrophage Recruitment to Inflammation Lesions using Highly Sensitive and Stable Radionuclide-Embedded Gold Nanoparticles as a Nuclear Bio-Imaging Platform
Authors: Sang Bong Lee, Ho Won Lee, Thoudam Debraj Singh, Yinghua Li, Sang Kyoon Kim, Sung Jin Cho, Sang-Woo Lee, Shin Young Jeong, Byeong-Cheol Ahn, Sangil Choi, In-Kyu Lee, Dong-Kwon Lim, Jaetae Lee, Yong Hyun Jeon
Journal: Theranostics (2017)

Reliable and sensitive imaging tools are required to track macrophage migration and provide a better understating of their biological roles in various diseases. Here, we demonstrate the possibility of radioactive iodide-embedded gold nanoparticles (RIe-AuNPs) as a cell tracker for nuclear medicine imaging. To demonstrate this utility, we monitored macrophage migration to carrageenan-induced sites of acute inflammation in living subjects and visualized the effects of anti-inflammatory agents on this process. Macrophage labeling with RIe-AuNPs did not alter their biological functions such as cell proliferation, phenotype marker expression, or phagocytic activity. In vivo imaging with positron-emission tomography revealed the migration of labeled macrophages to carrageenan-induced inflammation lesions 3 h after transfer, with highest recruitment at 6 h and a slight decline of radioactive signal at 24 h; these findings were highly consistent with the data of a bio-distribution study. Treatment with dexamethasone (an anti-inflammation drug) or GSK5182 (an ERRγ inverse agonist) hindered macrophage recruitment to the inflamed sites. Our findings suggest that a cell tracking strategy utilizing RIe-AuNPs will likely be highly useful in research related to macrophage-related disease and cell-based therapies.
Efficacy and Safety of CTL019 in the First US Phase II Multicenter Trial in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia: Results of an Interim Analysis
Authors: Shannon L Maude, Michael A Pulsipher, Michael W Boyer, Stephan A Grupp, Stella M Davies, Christine L Phillips, Michael R Verneris, Keith J August, Krysta Schlis, Timothy A Driscoll, Rajen Mody, Christian M Capitini, Carl H June, Bruce L Levine, Patricia A Wood, Lan Yi, John E Levine
Journal: Blood (2016)
Dyskerin Is Upregulated During Erythroid Differentiation of Human Hematopoietic Progenitor Cells and Hyperactivates Telomerase in Erythroid Precursor Cells
Authors: Ashu Kumari, Laura A Richards, Georg Jonquieres, Kathy Knezevic, Rosemary O'Brien, Christine E Napier, Jonathon Marks-Bluth, Hilda Pickett, John E Pimanda, Karen L MacKenzie
Journal: Blood (2012)
Safety and Risk of Allogeneic Peripheral Blood Stem Cell Donation: The Comprehensive Report of Nation-Wide Consecutively Pre-Registered 3,264 Family Donor Survey In 10years Project by Japan Society for Hematopoietic Cell Transplantation.
Authors: Yoshihisa Kodera, Kazuhito Yamamoto, Shunichi Kato, Mine Harada, Yoshinobu Kanda, Nobuyuki Hamajima, Shigetaka Asano, Yasuo Ikeda, Masahiro Imamura, Keisei Kawa, Yasuo Morishima, Tatsutoshi Nakahata, Mitsune Tanimoto, Hiroo Dohy, Ryuji Tanosaki, Shintaro Shiobara, Sung-Won Kim, Koji Nagafuji, Masayuki Hino, Koichi Miyamura, Ritsuro Suzuki
Journal: Blood (2010)
Precipitous Deterioration of Motor Function, Cognition, and Behavior
Authors: Mireya Fernández-Fournier, David C. Perry, Maria Carmela Tartaglia, Mary de May, Adam Boxer, Giovanni Coppola, Chadwick W. Christine, Eric J. Huang, William W. Seeley, Bruce L. Miller, Steven J. DeArmond, Lea T. Grinberg, Michael D. Geschwind
Journal: JAMA Neurology (2017)

A 72-year-old woman developed new-onset depression, sustained an unexplained fall, and started walking cautiously. After 1 year, her depression resolved but she developed a dry cough. One year later, she experienced a more rapid decline in her gait with parkinsonism, visual difficulties with restricted vertical gaze, slowed horizontal and vertical saccades, dysphagia, apathy, and progressive cognitive decline, which led to her death 2 years later. The differential diagnosis, neuroimaging, and pathological findings are discussed, as well as their public health implications.
Prevention of esophageal stricture after endoscopic submucosal dissection using RNA-based silencing of carbohydrate sulfotransferase 15 in a porcine model
Authors: Hiroki Sato, Seiji Sagara, Nao Nakajima, Teppei Akimoto, Kenji Suzuki, Hiroyuki Yoneyama, Shuji Terai, Naohisa Yahagi
Journal: Endoscopy (2017)

<b>Background and study aims</b> Endoscopic submucosal dissection (ESD) for esophageal carcinoma frequently causes fibrotic strictures that require treatment. A possible preventive effect of small interfering RNA (siRNA) targeting carbohydrate sulfotransferase 15 (CHST15) on esophageal stricture formation after ESD was investigated in 3 pigs. <b>Materials and methods </b>Two half-circumferential ESD ulcers were created in the oral and anal ends of the esophagus. CHST15 siRNA was injected submucosally in one of the two ESD ulcers. Endoscopic, macroscopic, histological, and polymerase chain reaction analyses were performed. <b>Results </b>On post-operative day 14, the non-treated ulcers were found to show histological fibrosis and increased expression of the CHST15 messenger RNA. A single endoscopic injection of CHST15 siRNA alleviated stricture development in post-ESD ulcers with significant reduction in the mucosal contraction rate. The deposition of collagen and accumulation of fibroblasts and myofibroblasts were diminished in ulcers treated with CHST15 siRNA, where significant suppression of CHST15, transforming growth factor-beta (TGF-β), and collagen-1 messenger RNAs was also seen. <b>Conclusion </b>CHST15 siRNA alleviated esophageal post-ESD stricture formation via repression of fibrosis, revealing a novel therapeutic role for antifibrotic agents in the prevention of post-ESD strictures.
Erratum: Proteomic identification of urinary biomarkers of diabetic nephropathy (Diabetes Care (2007) 30 (629-637))
Authors: P. V. Rao, Xinfang Lu, Melissa Standley, Patrick Pattee, G. Neelima, G. Girisesh, K. V. Dakshinamurthy, Charles T. Roberts, S. R. Nagalla
Journal: Diabetes Care (2007)
Reported Adverse Health Effects in Children from Ingestion of Alcohol-Based Hand Sanitizers — United States, 2011–2014
Authors: Cynthia Santos, Stephanie Kieszak, Alice Wang, Royal Law, Joshua Schier, Amy Wolkin
Journal: MMWR Morbidity and Mortality Weekly Report (2017)

Hand sanitizers are effective and inexpensive products that can reduce microorganisms on the skin, but ingestion or improper use can be associated with health risks. Many hand sanitizers contain up to 60%-95% ethanol or isopropyl alcohol by volume, and are often combined with scents that might be appealing to young children. Recent reports have identified serious consequences, including apnea, acidosis, and coma in young children who swallowed alcohol-based (alcohol) hand sanitizer (1-3). Poison control centers collect data on intentional and unintentional exposures to hand sanitizer solutions resulting from various routes of exposure, including ingestion, inhalation, and dermal and ocular exposures. To characterize exposures of children aged ≤12 years to alcohol hand sanitizers, CDC analyzed data reported to the National Poison Data System (NPDS).* The major route of exposure to both alcohol and nonalcohol-based (nonalcohol) hand sanitizers was ingestion. The majority of intentional exposures to alcohol hand sanitizers occurred in children aged 6-12 years. Alcohol hand sanitizer exposures were associated with worse outcomes than were nonalcohol hand sanitizer exposures. Caregivers and health care providers should be aware of the potential dangers associated with hand sanitizer ingestion. Children using alcohol hand sanitizers should be supervised and these products should be kept out of reach from children when not in use.
Mobile phone-delivered reminders and incentives to improve childhood immunisation coverage and timeliness in Kenya (M-SIMU): a cluster randomised controlled trial
Authors: Dustin G Gibson, Benard Ochieng, E Wangeci Kagucia, Joyce Were, Kyla Hayford, Lawrence H Moulton, Orin S Levine, Frank Odhiambo, Katherine L O'Brien, Daniel R Feikin
Journal: The Lancet Global Health (2017)

<h2>Summary</h2><h3>Background</h3> As mobile phone access continues to expand globally, opportunities exist to leverage these technologies to support demand for immunisation services and improve vaccine coverage. We aimed to assess whether short message service (SMS) reminders and monetary incentives can improve immunisation uptake in Kenya. <h3>Methods</h3> In this cluster-randomised controlled trial, villages were randomly and evenly allocated to four groups: control, SMS only, SMS plus a 75 Kenya Shilling (KES) incentive, and SMS plus 200 KES (85 KES = USD$1). Caregivers were eligible if they had a child younger than 5 weeks who had not yet received a first dose of pentavalent vaccine. Participants in the intervention groups received SMS reminders before scheduled pentavalent and measles immunisation visits. Participants in incentive groups, additionally, received money if their child was timely immunised (immunisation within 2 weeks of the due date). Caregivers and interviewers were not masked. The proportion of fully immunised children (receiving BCG, three doses of polio vaccine, three doses of pentavalent vaccine, and measles vaccine) by 12 months of age constituted the primary outcome and was analysed with log-binomial regression and General Estimating Equations to account for correlation within clusters. This trial is registered with ClinicalTrials.gov, number NCT01878435. <h3>Findings</h3> Between Oct 14, 2013, and Oct 17, 2014, we enrolled 2018 caregivers and their infants from 152 villages into the following four groups: control (n=489), SMS only (n=476), SMS plus 75 KES (n=562), and SMS plus 200 KES (n=491). Overall, 1375 (86%) of 1600 children who were successfully followed up achieved the primary outcome, full immunisation by 12 months of age (296 [82%] of 360 control participants, 332 [86%] of 388 SMS only participants, 383 [86%] of 446 SMS plus 75 KES participants, and 364 [90%] of 406 SMS plus 200 KES participants). Children in the SMS plus 200 KES group were significantly more likely to achieve full immunisation at 12 months of age (relative risk 1·09, 95% CI 1·02–1·16, p=0·014) than children in the control group. <h3>Interpretation</h3> In a setting with high baseline immunisation coverage levels, SMS reminders coupled with incentives significantly improved immunisation coverage and timeliness. Given that global immunisation coverage levels have stagnated around 85%, the use of incentives might be one option to reach the remaining 15%. <h3>Funding</h3> Bill & Melinda Gates Foundation.
A phase II study of GW786034 (pazopanib) in patients with recurrent or metastatic invasive breast carcinoma: Results after completion of stage I: A trial of the Princess Margaret Hospital Phase II Consortium
Authors: S. K. Taylor, S. Chia, S. Dent, M. Clemons, P. Grenci, L. Wang, A. M. Oza, P. Ivy, K. Pritchard, N. Leighl
Journal: Journal of Clinical Oncology (2009)

1133 Background: Pazopanib, an oral small molecule inhibitor of VEGFR, PDGFR, and KIT, has demonstrated activity in phase I, with a recommended phase II dose of 800 mg/d (Hurwitz H et al, J Clin Oncol. 2005;23[16 suppl]:3012.1). We evaluated the activity of single agent pazopanib in recurrent or metastatic breast cancer (MBC). Methods: In this 2-stage design, patients with recurrent or MBC received pazopanib 800 mg/d. The primary endpoint was objective response rate (ORR) of 20%. Response in 3 out of 18 patients was required to go to stage 2. Treatment was continued until progression. Results: 21 patients entered stage 1; 67% were ER positive and all were HER-2-negative. Prior lines of chemotherapy were 1 in 76% and 2 in 14%. Of the 19 evaluable patients, 2 patients remain on treatment. 14 (74%) stopped due to progressive disease, 2 (10%) due to adverse events, and 1 (5%) due to patient request. Best response was partial response (PR) in 1 (5%), stable disease (SD) in 11 (58%), and progressive disease in 7 (37%). Clinical benefit rate (CR, PR, or SD for ≥ 6 months) was 26%. Median time to progression (TTP) was 3.7 months (95% C.I. 1.7 months - not reached). 9 out of 18 patients (50%) with measurable target lesions had some decrease in target lesion size. Estimated progression-free survival at 3 months was 55%, and 28% at 6 months. Adverse events were grade 3/4 elevations in AST (14%) and ALT (10%), and grade 3 hypertension and neutropenia (14% each). Other common events were grade 1/2 lymphopenia, neutropenia, diarrhea, fatigue, skin hypopigmentation, hypertension, nausea, vomiting, anorexia, and headache. Conclusions: Pazopanib is well tolerated and demonstrates activity in pretreated breast cancer. While the target ORR of 20% has not been met, rates of SD and TTP are comparable to other active agents in this setting, and therefore pazopanib may be an interesting agent for future studies in breast cancer. [Table: see text]
Cbl Controls the Expression of Axl and Lyn Tyrosine Kinases Mediating Resistance to Nilotinib in Chronic Myeloid Leukemia Cells
Authors: Claire Tregoat, Romain Gioia, Valérie Lagarde, Valerie Prouzet-Mauleon, Éric Lippert, Audrey Sirvent, Serge Roche, Francois-Xavier Mahon, Jean-Max Pasquet
Journal: Blood (2012)
PP48. OUTCOME AND PROGNOSTIC FEATURES IN PAEDIATRIC PINEOBLASTOMAS: ANALYSIS OF CASES FROM THE SEER DATABASE.
Authors: Mr Soumya Mukherjee, Mr Senthil Selvanathan, Mr Paul Chumas
Journal: Neuro-Oncology (2017)

PURPOSE: Paediatric pineoblastomas are rare central nervous system tumours. Patient and treatment factors associated with outcome are poorly defined and limited to small retrospective case series and single case reports. Using the Surveillance, Epidemiology, and End Results (SEER) cancer registry, we investigated clinical and pathological factors associated with outcome in paediatric pineoblastomas. METHODS: Paediatric patients (<16 years old) with pineoblastomas diagnosed between 1990–2007 were identified from the SEER database. Kaplan-Meier survival analysis and Cox models were used to examine the effect of variables on overall survival. The variables analysed included patient’s age at diagnosis, gender, tumour spread and size, surgical resection and the use of adjuvant radiotherapy. RESULTS: Seventy-eight patients were identified from the database. Twelve patients were excluded as eleven had no surgery and one patient was excluded as the surgical status was unknown. Analysis of the remaining sixty-six patients revealed a median age at diagnosis of 5.5 years. Three patients underwent biopsy. Ten and seven patients underwent full and partial resection respectively. A further 46 patients underwent surgery the nature of which was not recorded. Thirty-nine patients (59.1%) received adjuvant radiotherapy. Eight patients (12.1%) had both surgery (Full or partial resection) and radiotherapy. The median overall survival was 40.5 months. Univariate analysis demonstrated that older age at diagnosis was the only positive predictor of overall survival. CONCLUSIONS: This study represents the largest analysis of paediatric pineoblastomas to date. The only relevant prognostic factor was older age at diagnosis. The role of surgery and adjuvant radiotherapy on overall survival remains to be defined.
Frequent in Vivo redundancy of C/EBPβ and C/EBPε during Myeloid Development
Authors: Nils Heinrich Thoennissen, Tadayuki Akagi, Sam Abbassi, Daniel Nowak, Ann George, Gay M. Crooks, C. Müller-Tidow, Adrian F Gombart, Phillip H Koeffler
Journal: Blood (2008)